ClinicalTrials.gg
CompletedNCT00287079CIS-ONUpdated Dec 27, 2013Results posted

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

A Phase 3 interventional study of Rebif® and No Treatment in Clinically Isolated Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Canada. Open to participants aged 18 Months to 65 Years. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Ages
18 Months to 65 Years
Sex
All
01

Study summary

The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that present with Clinically Isolated Syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI). The secondary objectives are to:

  • Assess the effectiveness of sc IFN beta - 1a (Rebif®) therapy in reducing the proportion of patients with CIS converting to CDMS
  • Assess the safety of sc IFN beta - 1a (Rebif®) in the patients with CIS
02

Conditions studied

  • Clinically Isolated Syndrome
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have experienced a first clinical episode suggestive of demyelinating disease
  • Subject must present with an abnormal MRI displaying at least 3 T2 weighted hyperintense lesions typical of multiple sclerosis (MS)
  • Subject must be greater than or equal to 18 years old
  • Subject must have had onset of the clinical attack within the last 120 days
  • Subject must give written
  • Female subjects must be neither pregnant nor breast feeding, and must not be of as defined by either:
  • Being or surgically sterile
  • Using hormonal , intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study

Subjects electing treatment:

  • Subject must be eligible for Interferon-beta 1-a therapy

Exclusion criteria

Exclusion Criteria:

  • Subject has evidence of other neurological diseases that could explain his/her symptomatology
  • Subject is pregnant or in lactation
  • Subject suffers from an intercurrent disease
  • Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the procedures required by this study
  • Subject has received immunomodulatory or therapy (including but not limited to cyclophosphamide, cyclosporine, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, campath), within 12 months of study day 1

Subjects electing treatment:

  • Subject has inadequate liver function, defined by total , (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the values
  • Subject has inadequate bone marrow reserve, defined as white blood cell count less than 0.5 times the lower limit of normal
  • Subject has a known allergy to IFN or any of the of the drug product
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Rebif®

    Drug: Rebif®

  • Other
    No Treatment

    Other: No Treatment

Interventions

  • 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks

  • OtherNo Treatment

    No treatment for 96 weeks

06

What researchers measure

Primary outcomes

  1. Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates

    CDMS was defined by the occurrence of a second exacerbation or relapse over 96 weeks in participants who presented with Clinically Isolated Syndrome (CIS) accompanied by an abnormal Magnetic Resonance Imaging (MRI) scan. Time was calculated from the date of the stabilization of the baseline CIS episode to the qualifying relapse for the CDMS.

    Time frame: Up to Week 96

Secondary outcomes

  1. Percentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS)

    CDMS was defined as the occurrence of a second exacerbation over 96 weeks in participants who presented with CIS accompanied by an abnormal MRI scan.

    Time frame: Up to Week 96

  2. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

    Time frame: Up to Week 96

07

Results

Posted Apr 4, 2012

Participant flow

Participant flow — Overall Study
MilestoneRebif 44 McgNo Treatment
Started323
Completed102
Not completed221
Withdrew: Qualifying relapse121
Withdrew: Non-qualifying relapse10
Withdrew: Adverse event50
Withdrew: Protocol violation10
Withdrew: Other30

Outcome measures

SecondaryPercentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS)

CDMS was defined as the occurrence of a second exacerbation over 96 weeks in participants who presented with CIS accompanied by an abnormal MRI scan.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS)
Percentage of participantsRebif 44 McgNo Treatment
Percentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS)37.533.3
SecondaryPercentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.

Time frame:
Up to Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
percentage of participantsRebif 44 McgNo Treatment
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)100—
PrimaryTime in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates

CDMS was defined by the occurrence of a second exacerbation or relapse over 96 weeks in participants who presented with Clinically Isolated Syndrome (CIS) accompanied by an abnormal Magnetic Resonance Imaging (MRI) scan. Time was calculated from the date of the stabilization of the baseline CIS episode to the qualifying relapse for the CDMS.

Time frame:
Up to Week 96
Reported as:
Mean · Month
Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates
MonthRebif 44 McgNo Treatment
Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates15.6 ± 1.2317.0 ± NA

Adverse events

Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif 44 Mcg—1/32 (3.1%)32/32 (100%)
No Treatment———
Most frequent serious events
Most frequent serious events
EventRebif 44 McgNo Treatment
Mild LeucopeniaBlood and lymphatic system disorders1/32—
Most frequent other events
Showing 10 of 31
Most frequent other events
EventRebif 44 McgNo Treatment
HeadacheNervous system disorders23/32—
FatigueGeneral disorders17/32—
ChillsGeneral disorders16/32—
PainGeneral disorders12/32—
NauseaGastrointestinal disorders10/32—
NasopharyngitisInfections and infestations9/32—
Influenza like illnessGeneral disorders7/32—
Injection site erythemaGeneral disorders5/32—
ParaesthesiaNervous system disorders5/32—
Injection site irritationGeneral disorders4/32—

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rebif 44 McgNo TreatmentTotal
Mean36.30 ± 9.6835.30 ± 13.3235.80 ± 11.50
Sex: Female, Male
Sex: Female, Male(Participants)Rebif 44 McgNo TreatmentTotal
Female19322
Male13013
08

Study locations

1 site
  • Canadian Medical Information Office
    Windsor, Barrie, Hamilton, Mississauga, Ontario, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2006
First posted
Feb 6, 2006
Start
Oct 2005
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Apr 4, 2012
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00287079
Collaborators
EMD Serono Canada Inc.
Responsible party
Sponsor
First posted
Feb 6, 2006
Start date
Oct 2005
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Apr 4, 2012
Last update
Dec 27, 2013

Study contacts

Medical Director
study director · EMD Serono Canada Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion